| Literature DB >> 33909109 |
Răzvan Bologheanu1, Mathias Maleczek2, Daniel Laxar3, Oliver Kimberger2.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) disrupts routine care and alters treatment pathways in every medical specialty, including intensive care medicine, which has been at the core of the pandemic response. The impact of the pandemic is inevitably not limited to patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their outcomes; however, the impact of COVID-19 on intensive care has not yet been analyzed.Entities:
Keywords: Clinical outcomes; ICU surge; Length of stay; Mortality; Preparedness planning
Mesh:
Year: 2021 PMID: 33909109 PMCID: PMC8080479 DOI: 10.1007/s00508-021-01857-4
Source DB: PubMed Journal: Wien Klin Wochenschr ISSN: 0043-5325 Impact factor: 2.275
Baseline characteristics before matching
| Characteristics | All patients | 2019 | 2020 | |
|---|---|---|---|---|
| 61 (50–72) | 62 (50–72) | 61 (48–72) | 0.6243a | |
| 972 (59.6%) | 850 (59.8%) | 122 (57.8%) | 0.6337b | |
| 88 (73–104) | 88 (74–104) | 85 (70–101) | 0.0111b | |
| – | – | – | 0.7457b | |
| 256 (15.7%) | 225(15.8%) | 31 (14.7%) | – | |
| 1376 (84.3%) | 1196 (84.2%) | 180 (85.3%) | – | |
| 75 (65–88) | 75 (65–89) | 75 (64–85) | 0.1959a | |
| – | – | – | 0.0298b | |
| 126 (7.7%) | 109 (7.7%) | 17 (8.1%) | – | |
| 90 (5.5%) | 86 (6.1%) | 4 (1.9%) | – | |
| 1046 (64.1%) | 892 (62.8%) | 154 (73%) | – | |
| 84 (5.1%) | 77 (5.4%) | 7 (3.3%) | – | |
| 181 (11.1%) | 162 (11.4%) | 19 (9%) | – | |
| 105 (6.4%) | 95 (6.7%) | 10 (4.7%) | – | |
| 855 (52.4%) | 731 (51.4%) | 124 (58.8%) | 0.0556b | |
| 668 (40.9%) | 585 (41.2%) | 83 (39.6%) | 0.6672b | |
| 223 (13.7%) | 196 (13.8%) | 27 (12.8%) | 0.7748b | |
| 139 (8.5%) | 117 (8.2%) | 22 (10.4) | 0.3509b | |
| 135 (8.3%) | 128 (9%) | 7 (3.3%) | 0.0076b | |
| 213 (13.1%) | 183 (12.9%) | 30 (14.2%) | 0.6675b | |
| 152 (9.3%) | 128 (9%) | 24 (11.4%) | 0.3286b | |
| 84 (5.1%) | 75 (5.3%) | 9 (4.3%) | 0.6496b | |
| 952 (58.3%) | 829 (58.3%) | 123 (58.3%) | 0.9502b | |
| 963 (59%) | 847 (59.6%) | 116 (55%) | 0.2297b | |
| 65 (4%) | 57 (4%) | 8 (3.8%) | 0.9710b | |
| 120 (7.4%) | 104 (7.3%) | 16 (7.6%) | 0.9966b | |
| 1376 | 1196 | 180 | 0.0013b | |
| 281 (20.4%) | 254 (21.2%) | 27 (15%) | – | |
| 93 (6.8%) | 80 (6.7%) | 13 (7.2%) | – | |
| 127 (9.2%) | 115 (9.6%) | 12 (6.7%) | – | |
| 72 (5.2%) | 61 (5.1%) | 11 (6.1%) | – | |
| 110 (8%) | 101 (8.4%) | 9 (5%) | – | |
| 346 (25.1%) | 297 (24.8%) | 49 (27.2%) | – | |
| 25 (1.8%) | 16 (1.3%) | 9 (5%) | – | |
| 97 (7%) | 75 (6.3%) | 22 (12.2%) | – | |
| 37 (2.7%) | 30 (2.5%) | 7 (3.9%) | – | |
| 118 (8.6%) | 104 (8.7%) | 14 (7.8%) | – | |
| 70 (5.1%) | 63 (5.3%) | 7 (3.9%) | – | |
| 256 | 225 | 31 | 0.0113b | |
| 17 (6.6%) | 12 (5.3%) | 5 (16.1%) | – | |
| 60 (23.4%) | 51 (22.7%) | 9 (29%) | – | |
| 95 (37.1%) | 91 (40.4%) | 4 (12.9%) | – | |
| 10 (3.9%) | 8 (3.6%) | 2 (6.5%) | – | |
| 50 (19.5%) | 41 (18.2%) | 9 (29%) | – | |
| 16 (6.3%) | 16 (7.1%) | 0 (0%) | – | |
| 8 (3.1%) | 6 (2.7%) | 2 (6.5%) | – | |
Values are reported as median (IQR interquartile range) or n (%). P-values are calculated using Mann-Whitney U test (a) or χ2 test (b)
SAPS III simplified acute physiology score III, ED emergency department, ICU intensive care unit, OR operating room, PACU post-anesthesia care unit, ENT otorhinolaryngology
Baseline characteristics after matching
| Characteristics | All patients | 2019 | 2020 | |
|---|---|---|---|---|
| 61 (48–71) | 61 (49–71) | 61 (48–72) | 0.9557a | |
| 256 (60.7%) | 134 (63.5%) | 122 (57.8%) | 0.2730b | |
| 85 (72–103) | 88 (74–105) | 85 (70–101) | 0.0641a | |
| 62 (14.7%) | 31 (14.7%) | 31 (14.7%) | – | |
| 360 (85.3%) | 180 (85.3%) | 180 (85.3%) | – | |
| 75 (65–87) | 77 (66–90) | 75 (64–85) | 0.1081a | |
| – | – | – | 0.2369b | |
| 28 (6.6%) | 11 (5.2%) | 17 (8.1%) | – | |
| 14(3.3%) | 10 (4.7%) | 4 (1.9%) | – | |
| 296 (70.1%) | 142 (67.3%) | 154 (73%) | – | |
| 17 (4%) | 10(4.7%) | 7 (3.3%) | – | |
| 40 (9.5%) | 21 (10%) | 19 (9%) | – | |
| 27(6.4%) | 17 (8.1%) | 10 (4.7%) | – | |
| 246 (58.3%) | 122(57.8%) | 124 (58.8%) | 0.9213b | |
| 161 (38.2%) | 78 (37%) | 83 (39.3%) | 0.6885b | |
| 52 (12.3%) | 25 (11.8%) | 27 (12.8%) | 0.8822b | |
| 49 (11.6%) | 27 (12.8%) | 22 (10.4%) | 0.5433b | |
| 13 (3.1%) | 6 (2.8%) | 7 (3.3%) | – | |
| 48 (11.4%) | 18 (8.5%) | 30 (14.2%) | 0.0916b | |
| 37 (8.8%) | 13 (6.2%) | 24 (11.4%) | 0.0852b | |
| 17 (4%) | 8 (3.8%) | 9 (4.3%) | – | |
| 249 (59%) | 126 (59.7%) | 123 (58.3%) | 0.8430b | |
| 239 (56.6%) | 123 (58.3%) | 116 (55%) | 0.5556b | |
| 15 (3.6%) | 7 (3.3%) | 8 (3.8%) | – | |
| 29 (6.9%) | 13 (6.2%) | 16 (7.6%) | 0.7003b | |
| 360 | 180 | 180 | – | |
| 54 (15%) | 27 (15%) | 27 (15%) | – | |
| 26 (7.2%) | 13 (7.2%) | 13 (7.2%) | – | |
| 24 (6.7%) | 12 (6.7%) | 12 (6.7%) | – | |
| 22 (6.1%) | 11 (6.1%) | 11 (6.1%) | – | |
| 18 (5%) | 9 (5%) | 9 (5%) | – | |
| 98 (27.2%) | 49 (27.2%) | 49 (27.2%) | – | |
| 18 (5%) | 9 (5%) | 9 (5%) | – | |
| 44 (12.2%) | 22 (12.2%) | 22 (12.2%) | – | |
| 14 (3.9%) | 7 (3.9%) | 7 (3.9%) | – | |
| 28 (7.8%) | 14 (7.8%) | 14 (7.8%) | – | |
| 14 (3.9%) | 7 (3.9%) | 7 (3.9%) | – | |
| 62 | 31 | 31 | – | |
| 10 (16.1%) | 5 (16.1%) | 5 (16.1%) | – | |
| 18 (29%) | 9 (29%) | 9 (29%) | – | |
| 8 (12.9%) | 4 (12.9%) | 4 (12.9%) | – | |
| 4 (6.5%) | 2 (6.5%) | 2 (6.5%) | – | |
| 18 (29%) | 9 (29%) | 9 (29%) | – | |
| 0 (0%) | 0 (0%) | 0 (0%) | – | |
| 4 (6.5%) | 2 (6.5%) | 2 (6.5%) | – | |
Values are reported as median (IQR interquartile range) or n (%). P-values are calculated using Mann-Whitney U test (a) or χ2 test (b)
SAPS III simplified acute physiology score III, ED emergency department, ICU intensive care unit, OR operating room, PACU post-anesthesia care unit, ENT otorhinolaryngology
Outcomes after propensity score matching
| Outcome | All patients | 2019 | 2020 | |
|---|---|---|---|---|
| 29 (6.8%) | 11 (5.2%) | 18 (8.5%) | 0. 2482b | |
| 53 (12.5%) | 23 (10.9%) | 30 (14.2%) | 0. 3781b | |
| 56 (13.3%) | 33 (15.6%) | 23 (10.9%) | 0.1965b | |
| 4 (2–7) | 4 (2–6) | 4 (2–7) | 0.3449a |
Values are reported as median (IQR interquartile range) or n (%). P-values are calculated using Mann-Whitney U test (a) or χ2 test (b)
ICU intensive care unit, LOS length of stay
Standardized differences for comparing means and prevalences (SMD) of matching variables between groups
| Covariate | SMD before matching | SMD after matching |
|---|---|---|
| 0.048 | 0.006 | |
| 0.04 | 0.116 | |
| 0.168 | 0.155 | |
| 0.037 | 0.048 | |
| 0.029 | 0.028 | |
| 0.075 | 0.074 | |
| 0.238 | 0.027 | |
| 0.039 | 0.179 | |
| 0.078 | 0.185 | |
| 0.047 | 0.024 | |
| 0.011 | 0.025 | |
| 0.01 | 0.056 | |
SAPS III simplified acute physiology score III